EPISODE · Dec 11, 2024 · 5 MIN
Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo
from Curie: Healthcare in Focus
On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.
Embed this episode
NOW PLAYING
Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo
0:00
5:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Curie: Healthcare in Focus?
This episode is 5 minutes long.
When was this Curie: Healthcare in Focus episode published?
This episode was published on December 11, 2024.
Can I download this Curie: Healthcare in Focus episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!